150 related articles for article (PubMed ID: 35854204)
1. Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System.
McDaniel LF; White MN; Obi EN; Kohinke RM; Lockhart ERS; Chipriano DJ; Chen Y; Everson NA
Infect Dis Ther; 2023 Jan; 12(1):95-107. PubMed ID: 35854204
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
Jiang Y; Sarpong EM; Sears P; Obi EN
Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
4. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
Whitney L; Nesnas J; Planche T
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
[TBL] [Abstract][Full Text] [Related]
6. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series.
Vargo CA; Bauer KA; Mangino JE; Johnston JE; Goff DA
Pharmacotherapy; 2014 Sep; 34(9):901-9. PubMed ID: 24898525
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.
Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M
Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
9. The Risk of
Hall RG; Cole TJ; Shaw C; Alvarez CA
Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326759
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
11. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for
Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA
Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada.
Wagner M; Lavoie L; Goetghebeur M
Can J Infect Dis Med Microbiol; 2014 Mar; 25(2):87-94. PubMed ID: 24855476
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
[TBL] [Abstract][Full Text] [Related]
15. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of
Alsoubani M; Chow JK; Rodday AM; Kent D; Snydman DR
Open Forum Infect Dis; 2024 Jan; 11(1):ofad622. PubMed ID: 38204563
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Budget Impact Analysis of Fidaxomicin Treatment for Clostridioides difficile Infections (CDI) in Germany.
Siefen AC; Kurte MS; Bauer AM; Cornely OA; Wingen-Heimann S; Kron F
Expert Rev Pharmacoecon Outcomes Res; 2024 May; ():. PubMed ID: 38712561
[TBL] [Abstract][Full Text] [Related]
18. A prospective, observational study of fidaxomicin use for
Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
20. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
